Loading...
•
Mar 31, 2021
Guardant Health Q1 2021 Earnings Report
Achieved revenue growth, driven by clinical tests, and launched Guardant Reveal for early-stage colorectal cancer.
Key Takeaways
Guardant Health reported a revenue of $78.7 million for the first quarter of 2021, a 17% increase compared to the corresponding period in 2020. The company launched Guardant Reveal and saw growth in clinical testing revenue, though it experienced a net loss of $109.7 million.
Revenue reached $78.7 million, a 17% increase year-over-year.
Clinical tests reported were 18,390, a 21% increase year-over-year.
Biopharmaceutical tests reported were 3,522, a 33% decrease year-over-year.
Guardant Reveal, a blood-only test for early-stage colorectal cancer, was successfully launched.
Guardant Health
Guardant Health
Guardant Health Revenue by Segment
Revenue by Segment
Oncology Revenue
CapyFin.com Forward Guidance
Guardant Health expects full year 2021 revenue to be in the range of $360 million to $370 million, representing 26% to 29% growth over full year 2020. Clinical volumes for 2021 are expected to be greater than 90,000 tests, growing at least 42% over 2020.
Positive Outlook
- Full year 2021 revenue is expected to be in the range of $360 million to $370 million.
- Revenue growth of 26% to 29% is expected over full year 2020.
- Clinical volumes for 2021 are expected to be greater than 90,000 tests.
- Clinical volume growth of at least 42% is expected over 2020.
- Expansion of product portfolio.
Challenges Ahead
- Continuing impacts of COVID
- Increased operating expenses
- Increased net loss
- Increased adjusted EBITDA loss
- Uncertainties related to forward-looking statements